ABSTRACT: Late Onset Central Hypoventilation Syndrome associated with Hypothalamic Dysfunction (LO-CHS/HD) is a distinct entity among the clinical and genetic heterogeneous group of patients with late onset central hypoventilation. Here we report a series of 13 patients with LO-CHS/HD. Rapid onset obesity is the first symptom of HD followed by hypoventilation with a mean delay of 18 mos. The outcome remains poor for this group of patients and would benefit from early diagnosis to anticipate ventilation and possible metabolic disorders. Tumor predisposition is more frequent than initially suspected and as high as 40% in this series. These tumors of the sympathetic nervous system (TSNS) are usually differentiated and do not significantly worsen the prognosis. We report a familial case with recurrence in siblings. The cause underlying LO-CHS/HD remains poorly understood although recurrence in siblings argues for a monogenic disorder. We ruled out PHOX2B, ASCL1, and NECDIN as disease-causing genes by direct sequencing in our series of patients and discuss possible disease-causing mechanisms. A genetic basis for C-CHS was postulated because of, i) concordant monozygotic twins; ii) rare cases of recurrence in siblings and vertical transmission; and iii) the association with genetically determined neurocristopathies (i.e. Hirschsprung disease and tumors of the sympathetic nervous system). The screening of genes involved in the developmental cascade of the autonomic nervous system pointed to PHOX2B as the gene underlying C-CHS with an autosomal dominant mode of inheritance and de novo mutations in the first generation (4). We and others subsequently showed that PHOX2B mutations also account for a subset of CHS presenting later in life and named Late-Onset Central Hypoventilation Syndrome (LO-CHS) (5-7). LO-CHS is genetically and clinically heterogeneous and a subset of patients presenting hypothalamic dysfunction (HD) in association with LO-CHS is clearly recognized as a distinct entity (8).
C entral Hypoventilation Syndrome (CHS) is persistent
central alveolar hypoventilation with or without apnoea during sleep (1) . The first cases defined as resulting from central hypoventilation were acquired and secondary to trauma, vascular events, infections, or tumors (2) . In 1970, Mellins et al. (3) reported the first case of idiopathic congenital central hypoventilation syndrome (C-CHS, Ondine's curse, MIM209880). A genetic basis for C-CHS was postulated because of, i) concordant monozygotic twins; ii) rare cases of recurrence in siblings and vertical transmission; and iii) the association with genetically determined neurocristopathies (i.e. Hirschsprung disease and tumors of the sympathetic nervous system). The screening of genes involved in the developmental cascade of the autonomic nervous system pointed to PHOX2B as the gene underlying C-CHS with an autosomal dominant mode of inheritance and de novo mutations in the first generation (4) . We and others subsequently showed that PHOX2B mutations also account for a subset of CHS presenting later in life and named Late-Onset Central Hypoventilation Syndrome (LO-CHS) (5) (6) (7) . LO-CHS is genetically and clinically heterogeneous and a subset of patients presenting hypothalamic dysfunction (HD) in association with LO-CHS is clearly recognized as a distinct entity (8) .
Single-case reports of LO-CHS/HD patients, one series and review of the literature have been reported and, thus, far (9 -22) for a total of 30 patients to date. Here we present a series of 13 additional patients with LO-CHS/HD, one being a familial case with recurrence in siblings. This observation strongly argues that LO-CHS/HD is a monogenic condition. In this series, PHOX2B, ASCL1, and NECDIN have been ruled out as disease-causing genes by direct sequencing.
PATIENTS AND METHODS
Thirteen patients with LO-CHS/HD were referred to us between 2000 and 2007 and medical records were reviewed. Inclusion criteria were i) central hypoventilation confirmed by polysomnographic recordings with normal brain MRI and no lung or neuromuscular diseases and ii) at least one other sign of hypothamic dysfunction among the following: rapid-onset obesity due to hyperphagia, hyperprolactinemia, central hypothyroidism, water balance disorder, nonresponse to growth hormone stimulation test, corticotrophin deficiency, or abnormal puberty (precocious or delayed).
The clinical data were first analyzed individually ( Table 1 ). The data were subsequently compared with the 15 cases reported in the literature since 1965 (Table 2 ) and the series of LO-CHS/HD published recently (Table 3) by the mean of simple statistical tests. The results are presented as median or mean Ϯ SD for quantitative variables and as percentages for nonquantitative variables.
Genetic studies. Blood samples were obtained with informed consent and DNA was extracted according to standard protocols. The ethics approval for this study was obtained from the ethics committee of the Medical Faculty of Necker Hospital (CCPRB No. 95-05-03). We screened the coding sequence of the PHOX2B, ASCL1 (previously named HASH-1), and NECDIN genes by direct DNA sequencing. The conditions for the analysis of ASCL1 and PHOX2B were as previously described (9, 10) . Primers used for PCR amplification of the NECDIN gene were as follows: exon 1 (F 5Ј-GCACTTC-CTCTCCAGGAATC-3Ј; R 5Ј-CTGGTTAGCCTCAGGTGCAG-3Ј), exon 2 (F 5Ј-ATGTGGTACGTGCTGGTCAA-3Ј; R 5ЈAACCATTCATCTGCCTC-CAG-3Ј). The PCR reaction mixture (25 L) contained 100 ng of leukocyte DNA, 20 pmol of each primer, 0.1 M dNTP, and 1 U TaqDNA polymerase (Invitrogen, Cergy Pontoise Cedex, France). DNA sequencing was performed by the fluorometric method on both strands (Applied Biosystems, Courtaboeuf Cedex, France). HLA genotyping was performed after amplification of the DRB1 locus by PCR with specific primers, and hybridization with allele-specific oligonucleotide probes immobilized on membrane-based strips (InnoLipa HLA-DRB1 typing kit, Innogenetics).
RESULTS
Clinical data from patients with LO-CHS/HD. Thirteen patients with LO-CHS/HD were included in this series. Median age at diagnosis was 5 y (from 1 mo to 9 y). Eleven cases were sporadic and two patients were brother and sister with healthy, unrelated parents. Although sibling two presented hypothalamic dysfunction and hypoventilation from birth, he was included considering the more typical presentation of his older sister. The main clinical findings are provided in Table  1 . The first symptom was rapid-onset obesity in 10 of 13 (77%) cases, behavioral abnormalities in two (15%) cases and alveolar hypoventilation in two (8%) cases. Rapid-onset obesity because of hyperphagia occurred in 12 of 13 patients and behavioral abnormalities are mentioned in 6 of 13 (46%) patients over the course of the disease.
Ventilation. Alveolar hypoventilation is consistent in our series as it was a mandatory criterion for inclusion. This choice aimed at collecting a homogeneous cohort of patients. Six of 13 (46%) patients required full-time artificial ventilation although the remaining patients needed ventilatory support during sleep only. Ventilatory support was provided by tracheotomy and mechanical ventilation in seven (54%) cases and positive airway pressure masks in six cases. When tested (seven cases), response to CO 2 was impaired or absent.
Hypothalamic disorders. Disorders of water balance were frequent. At least one episode of severe hypernatremia (Ͼ150 mM) was noted in 10 (77%) patients whereas seven (54%) patients presented at least one episode of hyponatremia (Ͻ130 mM). Six patients presented episodes of both hyper-and hyponatremia. Thirst was frequently impaired whether increased, reduced, or even absent. Indeed, adipsia was noted in seven (54%) patients and polydipsia in six (46%) patients. When tested, the capacity for urine concentration was retained with and no effect on desmopressin, ruling out both diabetes insipidus and inappropriate antidiuretic hormone secretion. Growth hormone deficiency was reported in seven patients among whom four had a clinical manifestation with deceleration of their growth rate. Other hypothalamic disorders were as follows: central hypothyroidism (6), poor thermoregulation (6), hyperprolactinemia (5), adrenal insufficiency (4), and abnormal puberty (no puberty in three cases at 14 y of age and precocious puberty in one case).
Dysautonomia. Ophthalmologic examination showed abnormal pupillary function in six cases, strabismus in five cases, and one case of bilateral ptosis.
Tumors of the sympathetic nervous system. Tumors of neural crest origin were identified in 5 of 13 (39%) cases. In two of them, thoracic and abdominal scan with thin slides was necessary to detect a tumor and (123) I-metaiodobenzylguanidine (MIBG) scintigraphy was not contributive. All tumors were differentiated and noninvasive with ganglioneuroma in three cases and neuroblastoma with no MYCN amplification in two other patients.
Neurodevelopment. Cognitive impairment during the course of the disease was assessed in six patients. None are following a typical school program for their age. Mood disorders and abnormal behavior are frequent, with lethargy and/or irritability and aggressivity mentioned in all six cases. Sleep disorders are also observed, but circadian cycle inversion is not mentioned. Of note, decreased pain sensitivity is mentioned in three cases.
Outcome. In this series, two patients died at 1 mo and at five and a half years after the onset of the disease. The cause of death was acute hypoventilation in the first case and severe hypernatremia in the second case.
Genetic study. We screened the coding sequence of PHOX2B, ASCL1, and NECDIN genes by direct sequencing in the 10 patients for whom DNA was available. No nucleotidic variations could be identified. We genotyped the HLA-DQ complex in nine patients and found five autoimmunity predisposing alleles, such as DQB1*0201, DQB1*0202, or DQB1*0302.
DISCUSSION
Idiopathic hypothalamic dysfunction was first described in 1982 as a probable consequence of the destruction or the degeneration of the hypothalamic-neurohypophyseal system, arising from the supraoptic and paraventricular nuclei of the hypothalamus (11) . Known causes of HD include hypothalamic tumors (germinoma, glioma, pinealoma, craniopharyngioma, and metastases), Langerhans cell histiocytosis; local inflammatory, autoimmune, or vascular diseases; sarcoidosis; midline cerebral and cranial malformations, and surgical or other traumas (12) .
We reviewed symptoms at onset, follow-up, and outcome in a series of 13 patients with LO-CHS/HD. The first manifestation was rapid-onset obesity, alveolar hypoventilation being noted later in the course of the disease with a mean of 1.5 y. Behavioral changes are frequently reported as a burden, which motivated the use of neuroleptic drugs in two cases (O28e1 and O310). Of note, lethargy, irritability, or a confused state can be attributed to water balance disorders. In our experience, the prognosis of LO-CHS/HD remains poor with a fatal outcome in two of the 13 patients and socio-educative difficulties in survivors. Alive (10) Alive (16) Died (0.15)
Alive (8) Alive (5) Alive (2.1)
Alive (5) Alive (9) Alive (5) Died (7) Alive (4) Alive (6) Alive ( Alive (8) Alive (2) Died at 8 y
Alive (10) Alive (5) Alive (12) Died at Abnormal autopsy: (1) supra medullary reticular gliosis (2) lymphocytic/histiocytic infiltrates of the hypothalamus, thalamus, and midbrain.
M, male; F, female; TSNS, tumor of the sympathetic nervous system; GN, ganglioneuroma; GNB, ganglianeuroblastoma; NB, neuroblastoma; CT, computed tomography; MRI, magnetic resonance imaging; FSH, follicle-stimulating hormone; LH, luteinic hormone; U, unknown.
Although rare in other LO-CHS entities, mental retardation is frequent in LO-CHS/HD patients in this series (six of 13; 34%). Neurocognitive deceleration appears at the onset of the disease although neurologic development had been considered to be in the normal range before. It remains difficult to assess whether mental deterioration occurs per se over the course of the disease or whether it is only secondary to metabolic disorders and/or hypoventilation in LO-CHS/HD. Early diagnosis is needed to equilibrate electrolytes and hormones, and to sustain adequate ventilatory support from onset. In case O310, adequate ventilatory support had no positive effect on cognition; a frontal disorder was assessed by neuropsychological evaluation and slow frontal wakes on EEG. Of note, other known genetic defects of pituitary development are frequently associated with mental retardation (such as FOXE-1/FKHL15 and NKX2.1 (13)).
Unlike LO-CHS, both LO-CHS/HD and C-CHS have been associated with tumors of neural crest origin (14) (8). Indeed, tumors of the sympathetic nervous system (TSNS) (i.e. ganglioneuroma and/or neuroblastoma) were diagnosed during the course of the disease in five of 13 patients from this series. Little is mentioned about such tumors in a series reported recently (15) . Putting together the series we reported and case reports, a TSNS was identified in 13 of 28 cases classified as follows: ganglioneuroma (7), ganglioneuroblastoma (2), and neuroblastoma stage 1 (3) . Age at onset of CHS is significantly younger in the group with no TSNS (3.6 versus 7.5 y old age, p Ͻ 0.01) and TSNS does not appear as a reliable prognostic factor. However, because these tumors are almost always differentiated and quiescent, their frequency may be underestimated.
LO-CHD/HD may be a paraneoplastic syndrome as proposed by North et al. (16) . Interestingly, necropsy of two patients with LO-CHS/HD revealed a TSNS (ganglioneuroma in one case and ganglioneuroblastoma in the other case) associated with lymphocytic infiltrates of the hypothalamus and the thalamus (16, 17) . Paraneoplastic manifestations in neuroblastoma have already been described with the opsoclonus-myoclonus syndrome being the most frequent (18) . However, autoantibodies such as anti-Hu have never been identified in the CSF of LO-CHS/HD patients. Moreover, TSNS are frequently diagnosed 1 to 2 y after the onset of the disease in LO-CHS/HD and surgery to remove the tumor does not seem to improve the outcome. Autoimmune LO-CHS/HD etiology is another hypothesis. Of note, one patient from this series (patient O276) has a complete IgG A deficiency, known to predispose to autoimmunity. In a recent familial case of narcolepsy where affected individuals did not carry the HLA DQB1*0602 autoimmunity-predisposing allele found in almost all other patients, a mutation in the hypocretin gene was found (19, 20) . Hypocretin neurons are localized in the lateral hypothalamus and their destruction lead to narcoplepsy. Interestingly, no autoimmunity predisposing allele segregates in the familial case of LO-CHS/HD. However, a larger series of patients is needed to conclude whether these preliminary results are significant and, importantly, predisposition to TSNS could hardly find an explanation according to the hypothesis of LO-CHS/HD being an autoimmune disorder.
All LO-CHS/HD cases reported previously have been sporadic, with men and women being similarly affected. We report a familial case with a brother and a sister born to healthy, nonrelated parents, being affected. This evokes an autosomal recessive or an autosomal dominant mode of inheritance with de novo mutation in most cases and germline mosaicism in one of the parents in the case with sibling recurrence. Monogenic inheritance of LO-CHS/HD is also based on animal models presenting both hypothalamic dysfunction and abnormal control of ventilation. Among these models, Necdin mutant mice have shown an abnormal respiratory rhythmogenesis and hypothalamic insufficiency (21, 22) . The NECDIN gene in human maps to 15q11-q13 at the Prader-Willi syndrome locus (PWS, MIM 176270). Patients with PWS can present endocrine abnormalities and respiratory manifestations but no tumor predisposition. However, no mutation in the coding sequence of the NECDIN gene could be identified in the nine LO-CHS/HD cases studied. Among genes implicated in both peripheral and CNS development, we also tested ASCL1 as a candidate gene for two reasons. First, Mash1, the murine homolog of ASCL1, is expressed throughout the basal retrochiasmatic neuroepithelium and is required for the generation of ventral neuroendocrine neurons (23) . Second, ASCL1 is a potential modifier gene of PHOX2B in C-CHS (9) . We also studied the sequence of PHOX2B, as it is the disease-causing gene in both C-CHS and a subset of LO-CHS, in LO-CHS/HD. We identified no mutations in the ASCL-1 or PHOX2B coding sequence in this series. These negative results strongly argue for genetic heterogeneity within the group of patients with LO-CHS. Serotonin and ␤-endorphin pathways are two other interesting candidate cascades. Serotoninergic neurons are found in the anterior ventromedial hypothalamus, and the respiratory control centers and their impairment could result in both hypothalamic dysfunction and central hypoventilation. Increased endorphin production leads to increased prolactin production and inhibition of gonadotrophin-releasing hormone and thyroid-stimulating hormone release. Moreover, ␤-endorphin diminishes the central respiration drive. Altogether, identification of the genetic causes underlying LO-CHS/HD will shed light on links between hypothalamic function, ventilation, and tumor predisposition.
